Questions discussed in this category
I am not sure there is much efficacy for a regimen that does not include asparaginase. The patient received 2 cycles of P-GemOx, then was admitted for...
At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...
Would you consider this de novo DLBCL (unable to assess for clonality)? How would you handle prior anthracycline exposure?
240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...
Would you still go to auto or consider allo?
Would you intercalate HD-MTX with her CHOEP?
2174920168189851835152001542415144142431304312818
Papers discussed in this category
Eur J Haematol, 2023 Mar 27
Ann Oncol, 2009 Jul 01
Blood, 2010 Jul 21
N Engl J Med, 2022 Jun 03
J Hematol Oncol, 2021 Oct 30
Blood advances, 2023 Sep 26
Scientific reports, 2022 Nov 29
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-10
Blood, 2015 Jun 24
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009 Oct 05